Artrya (ASX:AYA) said US non-profit health system Ascension agreed to participate in its multi-center clinical SAPPHIRE study, according to a Thursday filing with the Australian bourse.
The study, which will start in 2026, is designed to assess how the company's Salix cloud platform and plaque dispersion score can provide early detection of coronary artery disease, and includes a focus on improving care for women, the filing said.
Shares rose 3% in midday trade on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.